VisionGate, a Gig Harbor headquartered company working in the field of cancer diagnostics, has sold its first commercially available Cell-CT™ imaging platform to Arizona State University's Biodesign Institute. VisionGate's patented technology was developed with assistance from UW researcher Eric Seibel.
In a February 26th press release from ASU, Thomas Neumann, M.D., VisionGate’s vice president for medical science, said the sale of the company’s first Cell-CT platform is a significant step for the company. “We are encouraged that the scientists at the Biodesign Institute will be using our novel 3-D cellular imaging technology for their groundbreaking research on single cell biology,” he said. “VisionGate plans to continue developing the Cell-CT system for clinical use in the early detection of lung cancer, and the agreement announced today is expected to provide valuable contributions to the institute’s personalized medicine initiatives.”
Related external links (will open a new window):
Read more in the Arizona State University press release
Related WTC links:
VisionGate is a WTC client
VisionGate and University of Washington create 3-D cancer imaging
- end of post -
>> Start a discussion on this topic
In a February 26th press release from ASU, Thomas Neumann, M.D., VisionGate’s vice president for medical science, said the sale of the company’s first Cell-CT platform is a significant step for the company. “We are encouraged that the scientists at the Biodesign Institute will be using our novel 3-D cellular imaging technology for their groundbreaking research on single cell biology,” he said. “VisionGate plans to continue developing the Cell-CT system for clinical use in the early detection of lung cancer, and the agreement announced today is expected to provide valuable contributions to the institute’s personalized medicine initiatives.”
Related external links (will open a new window):
Related WTC links:
- end of post -
Labels: Company_and_Client_News, Life_Sciences, RTD, VisionGate
0 Comments:
Post a Comment
Your comments are encouraged. By posting a comment, you grant WTC the right to use the content for promotional or marketing purposes. We review comments during business hours before posting to our site.
<< Back to News Forum Home